Stephan Weidinger

Arnold Heller Str 3
Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 289 publications

Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

Journal: Dermatology and therapy

Published: August 28, 2026

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Journal: The Journal of dermatological treatment

Published: August 07, 2026

Response to letter to the editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Response to letter to the editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Journal: The Journal of dermatological treatment

Published: August 04, 2026

Author Correction: Atopic dermatitis.

Author Correction: Atopic dermatitis.

Journal: Nature reviews. Disease primers

Published: June 19, 2026

Dermkielia cavawata sp. nov. gen. nov., Isolated From Plantar Eczema.

Dermkielia cavawata sp. nov. gen. nov., Isolated From Plantar Eczema.

Journal: Mycoses

Published: June 08, 2026

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Journal: The Journal of dermatological treatment

Published: May 21, 2026

Atopic dermatitis.

Atopic dermatitis.

Journal: Nature reviews. Disease primers

Published: April 20, 2026

Non-communicable inflammatory skin diseases comprise clinically meaningful distinct endotypes as identified by non-hypothesized integration of phenotypic and transcriptome data.

Non-communicable inflammatory skin diseases comprise clinically meaningful distinct endotypes as identified by non-hypothesized integration of phenotypic and transcriptome data.

Journal: The Journal of allergy and clinical immunology

Published: April 16, 2026

Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry.

Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry.

Journal: Acta dermato-venereologica

Published: April 16, 2026

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.

Journal: Acta dermato-venereologica

Published: March 26, 2026

Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: An analysis from the TREATKids registry.

Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: An analysis from the TREATKids registry.

Journal: The Journal of investigative dermatology

Published: March 26, 2026

Patient treatment needs in atopic dermatitis: A real-world cohort study.

Patient treatment needs in atopic dermatitis: A real-world cohort study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 15, 2026

Showing 1-12 of 289

Last Updated: 09/26/2026